Summary & Overview
HCPCS J9248: Melphalan Injection, 1 mg
HCPCS Level II code J9248 denotes a 1 mg injection of melphalan (hepzato), an antineoplastic agent used in oncology care. This code is significant nationally because it standardizes reporting and billing for a specific chemotherapeutic supply, affecting coverage determinations, reimbursement flows, and clinical documentation across outpatient infusion centers and hospital outpatient departments. Consistent coding for chemotherapeutic agents supports quality measurement, utilization tracking, and payment integrity.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for melphalan injections, the typical sites of service where this HCPCS Level II code is used, and the common modifiers associated with chemotherapy supply billing. The publication presents benchmarks for payer coverage patterns, describes policy updates that commonly affect HCPCS drug coding and billing, and highlights operational considerations for service line managers and revenue cycle teams.
The content is intended for a national audience and focuses on coding, clinical setting, payer interactions, and administrative implications tied to HCPCS Level II code J9248. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9248 describes an injection of melphalan (hepzato), 1 mg. The service is a chemotherapy/antineoplastic drug administration supplied as a single-dose injectable medication. Typical site of service is an outpatient infusion center or hospital outpatient department, where parenteral chemotherapy agents are prepared and administered under clinician supervision.
Clinical & Coding Specifications
Clinical Context
A patient with multiple myeloma or another plasma cell dyscrasia is scheduled to receive systemic chemotherapy with melphalan for disease control or as part of a conditioning regimen prior to autologous hematopoietic stem cell transplantation. The drug in this billing descriptor, J9248 (injection, melphalan, 1 mg), is administered intravenously in a controlled oncology setting. Typical workflow: the oncology clinic or inpatient hematology unit performs a pre-treatment evaluation including recent labs (CBC with differential, renal and hepatic panels), medication reconciliation, and consent. Pharmacy compounds the appropriate melphalan dose based on body surface area or transplant protocol; the dose is prepared under sterile conditions and labeled. A registered nurse or infusion pharmacist verifies patient identity, checks premade orders, and establishes IV access. For outpatient infusions, the patient is monitored in the infusion center for vital signs, infusion tolerance, and acute adverse reactions; for conditioning regimens, administration occurs in an inpatient bone marrow transplant or oncology unit with extended monitoring. Documentation includes indication, dose (mg and number of J9248 units billed), route (IV), lot number, expiration, and any applicable modifier (for example, JW when discarding remainder). Billing uses J9248 units corresponding to the total milligrams administered, and relevant CPT codes are used for infusion encounter services, vascular access procedures, and supportive care as applicable.
Coding Specifications
| Modifier | Description |
|---|